Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine
ZURICH, SWITZERLAND, May 22, 2023 – (ACN Newswire) – Neurimmune announced today that primary results…
Month: May 2023
SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
HONG KONG, May 22, 2023 – (ACN Newswire) – A Hong Kong-based biopharmaceutical company dedicated…
AlmaLinux OS Foundation Welcomes Cybertrust Japan as a Platinum Sponsor
Collaboration aims to bring further stability and security to the RHEL clone FORT MYERS, Fla.–(BUSINESS…
Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8)…
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8)…
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant…
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the…
egnite, Inc. Announces Research from Its Real-World Database at Heart Rhythm 2023
– Study Led by John Mignone, M.D., Ph.D., Presented at the Heart Rhythm Society’s Annual…
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
— New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in…
The Barking Lounge Announces Luxury Mobile Pet Grooming Services in Miami
Doral, Florida–(Newsfile Corp. – May 20, 2023) – The Barking Lounge offers a variety of…
Creation Networks Inc Expands Services to Improve AV System Maintenance
Concord, California–(Newsfile Corp. – May 20, 2023) – Creation Networks Inc is now providing businesses…
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells,…
MarketMan Announces Next Generation of Premium Features Using Predictive Analytics for Food Service COGS Management
MarketMan’s New Suggestive Ordering and Cost of Goods Sold Over Time will be demonstrated at…
Kravets Wehby Gallery Proudly Presents ‘Alien in Spaces’, the First New York Solo Exhibition by Sejiro Avoseh
New York, New York–(Newsfile Corp. – May 20, 2023) – Kravets Wehby Gallery is thrilled…
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available…
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and…
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
Company to host conference call to discuss financial results and provide a corporate update on…